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ABSTRACT
Background: Computed tomography (CT) of the lungs is the gold standard for assessing the
extent of structural changes in the lungs. Spirometry-controlled chest CT (SCCCT) has improved
the usefulness of CT by standardising inspiratory and expiratory lung volumes during imaging.
This was a single-centre cross-sectional study in children with cystic fibrosis (CF). Using SCCCT we
wished to investigate the association between the quantity and extent of structural lung changes
and pulmonary function outcomes, and prevalence of known CF lung pathogens.
Methods: CT images were analysed by CF-CT scoring (expressed as % of maximum score) to
quantify different aspects of structural lung changes including bronchiectasis, airway wall thick-
ening, mucus plugging, opacities, cysts, bullae and gas trapping. Clinical markers consisted of
outcomes from pulmonary function tests, microbiological cultures from sputum and serological
samples reflecting anti-bacterial and anti-fungal antibodies.
Results: Sixty-four children with CF, median age (range) of 12.7 (6.4–18.1) years, participated in
the study. The median (range) CF-CT total score in all children was 9.3% (0.4–46.8) with gas
trapping of 40.7% (3.7–100) as the most abundant finding. Significantly higher median CF-CT
total scores (21.9%) were found in patients with chronic infections (N = 12) including Gram-
negative infection and allergic bronchopulmonary aspergillosis (ABPA) exhibiting CF-CT total
scores of 14.2% (ns) and 24.0% (p < 0.01), respectively, compared to 8.0% in patients with no
chronic lung infection. Lung clearance index (LCI) derived from multiple breath washout exhib-
ited closest association with total CF-CT scores, compared to other pulmonary function outcomes.
Conclusions: The most prominent structural lung change was gas trapping, while CF-CT total
scores were generally low, both showing close association with LCI. Chronic lung infections,
specifically in the form of ABPA, were associated with increased scores in lung changes. Further
investigation of impact of infections with different microorganisms on extent and progression of
structural CF lung disease is needed.
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Introduction
Structural lung changes such as bronchiectasis, airway
wall thickening, mucus plugging, opacities, cysts, bullae
and gas trapping are very common in patients with
cystic fibrosis (CF) and caused by a vicious cycle of
mucus stagnation, inflammation, and infection.[1,2]
Progression of structural lung changes is a sign of wor-
sening lung disease that will eventually lead to increased
morbidity and mortality.[3] Timely detection should
lead to changes in therapy to stop further progression,
and is thus essential to improve the long term outcome.
Computed tomography (CT) of the lungs is the gold
standard for assessing the extent of structural changes
in the lungs,[4,5] and manoeuvres for controlling
breath holds during imaging has further improved the
usefulness of CT by standardising lung volumes. This
standardisation improves the cross-sectional and long-
itudinal comparability between groups and within sub-
jects with repeated examinations,[6–8] and increases
the recognition of gas trapping.[9]
Monitoring and treating the microbiological patho-
gens in CF patients is a fundamental part of CF man-
agement.[10] The impact of chronic Gram-negative
infections on the progression of structural CF lung
disease and deteriorating pulmonary function and
quality of life is well established.[11–15] Another
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well-known risk factor for progression of CF lung dis-
ease is development of allergic bronchopulmonary
aspergillosis (ABPA) [16] whereas the general impact
including structural changes of infection with
Aspergillus fumigatus, allergy or not, is less well sub-
stantiated.[17–19]
Spirometry may be a suboptimal tool for monitoring
early CF lung disease,[20,21] whereas multiple breath
gas washout (MBW) assessing lung clearance index
(LCI) seems to be more promising,[22] and may have
better sensitivity to detect small airways disease relative
to spirometry. The importance of this remains to be
validated. However, normal LCI values have been
reported in individual CF patients with structural lung
changes on CT and vice versa.[23] Therefore, applic-
ability of MBW as complimentary to CT in describing
the state of lung disease still needs to be investigated.
The purpose of this study was to investigate the
association between the quantity and extent of struc-
tural lung changes using refined spirometry controlled
chest computed tomography (SCCCT) with computer-
animated feedback and clinical markers of CF lung
disease such as pulmonary function outcomes, and
prevalence of known CF lung pathogens in a cohort
of clinically stable CF children.
We hypothesized that children with chronic Gram-
negative lung infection or ABPA would present signif-
icantly more abundant structural changes. Second, we
hypothesized that LCI would serve as the marker with
closest association with CF-CT scores, compared to
other pulmonary function outcomes.
This study was presented in abstract form as part of
workshop 20 (Indexing the lung) at the European Cystic
Fibrosis Conference in Gothenburg, 11–14 June 2014.
Materials and methods
Study design and inclusion criteria
This study was a cross-sectional, single-occasion, and
single-centre study of 6–18 year old children diagnosed
with CF according to characteristic clinical features,
positive sweat test, and CFTR mutations.[24] All were
followed at CF Centre Copenhagen at Rigshospitalet,
Copenhagen, Denmark between 2011 and 2012. All
clinically stable children, i.e. without signs of exacerba-
tion as defined below, were eligible and consent was
obtained from the patient and/or parents. Inclusion
was postponed at least 4 weeks after the resolution of
symptoms and two or more signs of exacerbation:
cough, malaise, dyspnoea, increased sputum produc-
tion, anorexia, or decline in lung function >10% from
baseline values.[25]
In order to evaluate whether the study cohort was
representative of the total cohort of children at the
centre, a comparison was done between the included
and non-included patients according to: (1) lung func-
tion (FEV1 and FVC); (2) frequency of chronic Gram-
negative infections; and (3) level of specific
Pseudomonas aeruginosa IgG antibodies [26] and mar-
kers of Aspergillus lung infection (levels of specific anti-
Aspergillus IgG antibodies) [27] from the same time
span as the examinations performed in the study
cohort.
Examinations
The study was performed on a single occasion where
patients were examined using SCCCT, pulmonary
function tests, and a clinical evaluation by a specialised
CF physician.
Computed tomography
SCCCT examinations of the lungs were conducted
using real-time spirometric monitoring and biofeed-
back computer software in which inspiratory and
expiratory image sequences were captured at lung
volumes close to total lung capacity and close to
expiratory residual volume, respectively. During CT
scanning, lung volumes were displayed in real time
on a small monitor simultaneously showing an incen-
tive animation and depicting the threshold volumes of
expiratory reserve volume (ERV) and total lung capa-
city (TLC) as horizontal lines to be reached during
successful breath hold, as described previously.[9]
Only when required inspiratory and expiratory thresh-
old volumes were reached, image acquisition was
initiated by signalling to the CT technician. All scans
were performed by volumetric spiral CT imaging on a
Toshiba Aquillion 64 CT scanner (Toshiba
Corporation, Tokyo, Japan) with 100 kVp, mAs-mod-
ulation (SD = 19 in inspiratory sequences and SD = 27
in expiratory sequences, rotation 0.4 s). Additional
information and specifications can be found in the
Appendix.
CF-CT scoring
Structural lung changes visualised on CT were quantified
using the CF-CT scoring system for evaluating the extent
and severity of central and peripheral bronchiectasis,
airway wall thickening, central and peripheral mucus
plugging, opacities, cysts and bullae on inspiratory
images, and the extent and pattern of gas trapping on
expiratory images.[28] Scores were reported as a percen-
tage of the maximum theoretical score of 243 points.
Prior to the study, the observer (TK) was trained and
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certified in the CF-CT scoring system;[29] see Appendix
(Figure A1) for details. When scoring the study cohort,
the observer was blinded to the clinical backgrounds of
the subjects by assigning random unique case numbers
to CT examinations prior to scoring.
Microbiology and serum markers of infection
Routine clinical data have been collected prospectively
in the central database for several years. For this study
clinical data from the year prior to the study visit were
retrieved from the database. Three groups were identi-
fied depending on the infection status: (1) chronic
Gram-negative infection with P. aeruginosa,
Achromobacter xylosoxidans or Burkholderia cepacia;
(2) ABPA; or (3) Neither 1 nor 2.
Chronic infection was defined and based on growth
of the respective bacteria in >50% of months in the
previous year and increase in specific IgG antibodies
against Gram negative bacteria.[30–32] ABPA diagno-
sis consisted of clinical deterioration, increased serum
markers (total IgE>500 IU ml–1, elevated specific
Aspergillus IgE and Aspergillus IgG), and new or recent
abnormalities on chest radiographs.[33] All patients
ever diagnosed with ABPA were included in the
ABPA group since ABPA was considered a chronic
condition independent of duration prior to the study,
and with a continued risk of exacerbation.[33]
Pulmonary function tests
Spirometry and whole body plethysmography were per-
formed according to ATS and ERS recommendations [34]
using Jaeger Master Screen Pro (CareFusion, Hochberg,
Germany). Reference equations from the Global Lung
Initiative [35] and from Koopman et al. [36] were used
to standardise spirometry outcomes, and static lung
volume outcomes from plethysmography, respectively.
Nitrogen (N2) MBW measurements were performed
using Exhalyzer D (Eco Medics AG, Duernten,
Switzerland) in accordance with guidelines recom-
mended in the recent ERS/ATS consensus statement.
[37] Outcomes from MBW were calculated in
Spiroware (v. 3.1.6 ext.; Eco Medics AG, Duernten,
Switzerland) using standard software settings.
Statistical analysis
Comparisons between groups of patients were per-
formed using non-parametric Mann–Whitney tests
(continuous variables) and Fisher’s exact test (frequen-
cies). Spearman rank correlation and regression analyses
were used to calculate the relation between pulmonary
function test outcomes and CF-CT scores.
Statistical models and calculations were made with
guidance from the statistical advisory service at the
University of Copenhagen, using SAS Enterprise
Guide version 5.1. (SAS Institute Inc. NC, USA).
P-values <0.05 were considered significant.
Ethics
This study was approved by the Danish National
Committees on Biomedical Research Ethics, Capital
Region of Copenhagen (Protocol no.: H-1-2010-042).
The clinical database at the centre was approved by the
Danish Data Protection Agency (2008-41-2682).
Results
Study population
A total of 78 children from the paediatric CF cohort
counting N = 105 children were eligible based on age
between 6 and 18 years, and 64 (82.1%,) were included in
the study. Characteristics and main results of the study are
outlined in Table 1. No significant differences were found
between the included and the 14 non-included children
(see Appendix (Figure A1) for details). Among the non-
included children 12 simply declined (no explanations) to
participate within the duration of the inclusion period, one
refused due to fear of ionizing radiation, and in one the
SCCCT seemed non-feasible during the training session.
CF-CT: Feasibility and scores
The feasibility of imaging using spirometry control was
excellent (98.4%); only one examination showed
motion artefacts due to inspiration during imaging
manoeuvres (1.6%).
The CF-CT scores, CF-CT total score and scores
according to each domain, in the total group of 64
Table 1. Demographics, CF-CT scores and pulmonary function
test results.
Demographics N Median Minimum Maximum
Age (years) 64 12.7 6.4 18.1
BMI z-score 64 −0.2 −2.2 1.5
CF-CT scores
CF-CT total score (%) 64 9.3 0.4 46.8
Bronchiectasis (%) 64 5.6 0.0 54.5
Airway wall thickening (%) 64 7.9 0.0 44.4
Mucus plugging (%) 64 1.4 0.0 52.8
Parenchyma (%) 64 0.9 0.0 11.1
Gas trapping (%) 64 40.7 3.7 100.0
Pulmonary function tests
LCI 62 9.3 6.2 16.0
FEV1 % predicted 64 96.1 45.1 118.5
FVC % predicted 64 97.8 53.8 128.2
FEF25-75 % predicted 64 88.0 20.5 150.6
RV/TLC z-score 55 0.4 −1.9 3.2
EUROPEAN CLINICAL RESPIRATORY JOURNAL 3
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children are outlined in Table 1 and the frequency (%)
distribution of the CF-CT total score is displayed in
Figure 1(a). A large proportion of subjects exhibited
marked gas trapping (Figure 1(b)), whereas the propor-
tions showing changes in the other domains were very
low (not shown).
Microbiology: impact of infection status
Significantly higher median CF-CT total scores (21.9%)
were found in patients with chronic infections (N = 12)
compared with 8.0% in patients with no chronic lung
infection, though with large variations in the scores
(Figure 2(a)). The median CF-CT total score in the
small groups with chronic Gram-negative infections
(N = 5) and ABPA (N = 7) were 14.2% (NS) and 24.0%
(p < 0.01), respectively (Appendix (Figure A1)). Marked
gas trapping was shown in all groups irrespective of
infection, thus exhibiting a median of 38.9% gas trapping
in patients without infection and 62.0% (p < 0.01) with
chronic infection, again showing large variation within
groups (Figure 2(b) and Appendix (Figure A2)).
Pulmonary function tests
The outcome of pulmonary function tests with the
closest correlation to CF-CT total score and gas trap-
ping was the LCI derived from MBW (Figures 3 and 4),
and LCI was also the outcome with the highest regres-
sion value using linear regression, thus describing the
highest amount of the variation in CF-CT total score
(Table 2).
Figure 1. Frequency distribution of CF children according to: (a) CF-CT total score and (b) gas trapping score. Percentage (Y-axis) of
the given score (X-axis) is shown as bars and absolute numbers on top of each bar.
Figure 2. CF-CT total scores in % of maximal theoretical score and percentage of gas trapping according to infection status. (a) CF-
CT total score, Mann–Whitney: p = 0.0028. (b) Gas trapping score, Mann–Whitney p = 0.0702. Data are presented as box and
whiskers plots representing the 25th and 75th centiles and the range, respectively.
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Discussion
We investigated the structural lung changes in CF chil-
dren with mild clinical disease using SCCCT refined by
a computer-animated biofeedback system invented to
further standardise lung volumes during CT examina-
tions and to increase feasibility. The CF-CT total scores
were generally low in this closely monitored CF cohort,
whilst gas trapping was prominent in the majority of
Table 2. Correlation coefficients and regression values between
outcomes of pulmonary function tests and CF-CT total scores.
Pulmonary function tests outcomes r R2
FEF25-75 %-pred. −0.441* 0.192*
FEV1 %-pred. −0.353* 0.242**
FVC %-pred. −0.208 0.128*
LCI 0.739** 0.536**
RV/TLC z-score 0.607** 0.314**
FEF25-75%: Forced expiratory flow within 25 and 75% of FVC. FEV1: forced
expiratory volume in 1 sec. FVC: forced vital capacity. LCI: lung clearance
index. RV: residual volume. TLC: total lung capacity. *p < 0.05, **p < 0.0001.
Figure 3. CF-CT total score (%) and the relationship to LCI (r = 0.739, p < 0.0001) in all N = 64 participants.
Figure 4. Gas trapping score (%) and the relationship to LCI (r = 0.633, p < 0.0001) in all N = 64 participants. Markers designate: no
chronic infection, chronic Gram negative infection or ABPA as shown in legends.
EUROPEAN CLINICAL RESPIRATORY JOURNAL 5
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patients. Gas trapping has previously also been reported
as a common abnormality in very young children with
CF using volume controlled CT scans,[38] as well as in
studies without breath hold control.[4] We have pre-
viously demonstrated the superiority of SCCCT to
detect gas trapping in comparable cohorts of children
examined without definite breath hold control display-
ing no or only very mild gas trapping in 19% of cases,
compared to only 4.5% of cases in the cohort where
volume control was used during CT imaging.[9]
Accurate identification of structural lung changes is of
great importance to the usefulness of CT examinations,
especially for longitudinal studies. Controlling lung
volume during imaging seems to be a tool that improves
this accuracy.[8,39]
LCI was the pulmonary function outcome with the
closest correlation to CF-CT total scores, which is in
agreement with reports from other groups claiming
LCI as being highly reliable in predicting CF structural
lung damage.[4,20,22,23] Furthermore, we are report-
ing similar correlations between other pulmonary func-
tion outcomes and CF-CT scores in consistency with
previous reports.[4,20,22,23]
The importance of CT as a supplementary tool in
monitoring and management of children with CF is
supported by the findings of this study since LCI only
describes approximately half of the variation in the CF-
CT total score. Thus valuable information would have
been undiscovered if only LCI was used to predict the
extent of structural lung changes.
An important strength of the study was the use of a
computer-animated biofeedback to standardise breath
hold. This method seems feasible in all age groups, and
provides a high degree of consistency in the execution of
all SCCCT examinations, which, in addition, were per-
formed by a single person (TK). Good inter-observer
agreement with an experienced observer regarding the
CF-CT scoring system was confirmed on training CT
scans from the Erasmus Medical Centre in Rotterdam,
the Netherlands, prior to the scoring in this study, which
has previously been proposed as an improvement in the
utility of scoring systems.[40] Thus, the weakness of hav-
ing only one observer was addressed, although assess-
ment of intra-observer variability was not performed.
Furthermore, the observer was blinded to the clinical
condition and data during scoring.
The cross sectional design combined with retrospec-
tively collected clinical data might have weakened the
study, and longitudinal studies prospectively collecting
such data are needed to investigate the associations
between various infections, e.g. pulmonary aspergillosis
and structural lung changes. With regard to the risk of
selection bias, the analysis between the included and the
excluded patients did in no way show any statically sig-
nificant differences. The CF-CT scoring systemmight not
have been the optimal system to quantify the extent of
structural changes in this group of children with mild
disease, where the majority received low scores. Other
scoring systems developed explicitly for early disease,
such as the PRAGMA system,[41] might prove to be
superior to the CF-CT scoring system in such cases.
A refined SCCCT using computer-animated biofeed-
back was applied in this study to standardise breath hold
during CT imaging. Significant prominence of gas trap-
ping was shown in CF children with mild disease but the
clinical impact of this is not yet known and further
longitudinal studies using SCCCT or other methods of
breath hold control are needed for verification.
Despite the low number of chronically infected chil-
dren we did explore the impact of chronic Gram-nega-
tive lung infections and ABPA on the presence of
structural lung changes and found an overall signifi-
cant impact attributable to ABPA. Future, larger stu-
dies should investigate manifestations of Aspergillus
fumigatus infection with or without allergy since the
impact of this is less substantiated.[17–19]
In conclusion the most prominent structural lung
change was gas trapping, while CF-CT total scores
were generally low. Chronic lung infections, specifically
in the form of ABPA, were associated with increased
lung changes. The CT examinations cannot be fully
replaced by any lung function measurements such as
LCI, or other clinical markers in the detection of pul-
monary damage in CF. Further investigation into impact
of infections with different microorganisms on extent
and progression of structural CF lung disease is needed.
Acknowledgements
The authors would like to thank the John & Birthe Meyer
Foundation and the Toyota Foundation for financial support,
the Department of Diagnostic Imaging, and chief technician
Flemming Dalsgaard for setting up the scanning protocol.
The spirometric monitoring software was developed by bio-
engineer Björn Neumann Jensen and Thomas Kongstad with
inspiration from lung function technician Sandra Lever,
Erasmus MC, Rotterdam, the Netherlands.
Disclosure statement
No potential conflict of interest was reported by the authors.
Funding
This work was supported by the Toyota Foundation; Meyer
Foundation.
6 T. KONGSTAD ET AL.
D
ow
nl
oa
de
d 
by
 [C
op
en
ha
ge
n U
niv
ers
ity
 L
ibr
ary
] a
t 0
4:3
2 2
5 O
cto
be
r 2
01
7 
Notes on contributors
Thomas Kongstad is a Medical Doctor and Ph.D. He is
currently working at the pediatric department at Herlev
and Gentofte Sygehus, Copenhagen, Denmark, and is scien-
tifically working with Cystic Fibrosis and HRCT at the
Pediatric pulmonary service centre at Rigshospitalet,
Copenhagen Denmark.
Kent Green is a Medical Doctor and Ph.D. He is currently
working at the pediatric department at Rigshospitalet,
Copenhagen, Denmark, and is scientifically working with
advanced pulmonary function measurements at the
Pediatric pulmonary service centre at Rigshospitalet,
Copenhagen Denmark.
Frederik Buchvald is a Medical Doctor and Ph.D. He is
currently working at the pediatric department at
Rigshospitalet, Copenhagen, Denmark, and is scientifically
working with Diffuse lung disease in children at the
Pediatric pulmonary service centre at Rigshospitalet,
Copenhagen Denmark.
Marianne Skov is a Medical Doctor and Ph.D. She is cur-
rently working with CF in children at the pediatric depart-
ment at Rigshospitalet Copenhagen, Denmark, and is
scientifically working with Cystic Fibrosis at the
Copenhagen CF centre at Rigshospitalet, Copenhagen
Denmark.
Tania Pressler is a Medical Doctor and Dr. of medical
science, and head of the Copenhagen CF centre. She is
currently working with CF in children and adults at
Rigshospitalet Copenhagen, Denmark, and is scientifically
working with Cystic Fibrosis at the Copenhagen CF centre
at Rigshospitalet, Copenhagen Denmark.
Kim Gjerum Nielsen is a Medical Doctor and Dr. of medical
science, and head of the Pediatric pulmonary service centre.
He is currently working at the pediatric department at
Rigshospitalet Copenhagen, Denmark, and is scientifically
working with Primary Cilia Dyschinesia, Cystic Fibrosis,
and Diffuse lung disease in children at the Pediatric pulmon-
ary service centre at Rigshospitalet, Copenhagen Denmark.
ORCID
Thomas Kongstad http://orcid.org/0000-0001-6679-5174
References
1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am
J Respir Crit Care Med. [Internet]. 1996;154:1229–1256.
Available from: http://www.ncbi.nlm.nih.gov/entrez/
query . fcgi?cmd=Retr ieve&db=PubMed&dopt=
Citation&list_uids=8912731
2. Koch C. Early infection and progression of cystic fibro-
sis lung disease. Pediatr Pulmonol. [Internet].
2002;34:232–236. Available from: http://www.ncbi.nlm.
nih .gov/entrez/query . fcg i?cmd=Retr ieve&db=
PubMed&dopt=Citation&list_uids=12203855.
3. Loeve M, Van Hal PT, Robinson P, et al. The spectrum
of structural abnormalities on CT scans from patients
with CF with severe advanced lung disease. Thorax.
[Internet]. 2009;64:876–882. Available from: http://
www.ncbi .nlm.nih.gov/entrez/query.fcgi?cmd=
Retrieve&db=PubMed&dopt=Citation&list_uids=
19541686.
4. Brody AS, Klein JS, Molina PL, et al. High-resolution
computed tomography in young patients with cystic
fibrosis: distribution of abnormalities and correlation
with pulmonary function tests. J Pediatr. [Internet].
2004;145:32–38. Available from: http://www.ncbi.nlm.
nih .gov/entrez/query . fcg i?cmd=Retr ieve&db=
PubMed&dopt=Citation&list_uids=15238903
5. De Jong PA, Nakano Y, Lequin MH, et al. Progressive
damage on high resolution computed tomography
despite stable lung function in cystic fibrosis. Eur
Respir J. [Internet]. 2004;23:93–97. Available from:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=
Retrieve&db=PubMed&dopt=Citation&list_uids=
14738238.
6. Robinson TE. Computed tomography scanning techni-
ques for the evaluation of cystic fibrosis lung disease.
Proc Am Thorac Soc. [Internet]. 2007;4:310–315.
Available from: http://www.ncbi.nlm.nih.gov/entrez/
query . fcgi?cmd=Retr ieve&db=PubMed&dopt=
Citation&list_uids=17652492
7. Long FR, Castile RG. Technique and clinical applica-
tions of full-inflation and end-exhalation controlled-
ventilation chest CT in infants and young children.
Pediatr Radiol. [Internet]. 2001;31:413–422. Available
from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=
11436888
8. Mueller KS, Long FR, Flucke RL, et al. Volume-mon-
itored chest CT: a simplified method for obtaining
motion-free images near full inspiratory and end expira-
tory lung volumes. Pediatr Radiol. [Internet].
2010;40:1663–1669. Available from: http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=20508926
9. Kongstad T, Buchvald FF, Green K, et al. Improved air
trapping evaluation in chest computed tomography in
children with cystic fibrosis using real-time spirometric
monitoring and biofeedback. J Cyst Fibros. [Internet].
2013;12:559–566. Available from: http://www.ncbi.nlm.
nih .gov/entrez/query . fcg i?cmd=Retr ieve&db=
PubMed&dopt=Citation&list_uids=23810566
10. Döring G, Hoiby N. Early intervention and prevention
of lung disease in cystic fibrosis: a European consensus.
J Cyst Fibros. [Internet]. 2004;3:67–91. Available from:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=
Retrieve&db=PubMed&dopt=Citation&list_uids=
15463891
11. Kerem E, Viviani L, Zolin A, et al. Factors associated
with FEV1 decline in cystic fibrosis: analysis of the
ECFS patient registry. Eur Respir J. [Internet].
2014;43:125–133. Available from: http://www.ncbi.nlm.
nih .gov/entrez/query . fcg i?cmd=Retr ieve&db=
PubMed&dopt=Citation&list_uids=23598952.
12. Konstan MW, Wagener JS, VanDevanter DR.
Characterizing aggressiveness and predicting future
EUROPEAN CLINICAL RESPIRATORY JOURNAL 7
D
ow
nl
oa
de
d 
by
 [C
op
en
ha
ge
n U
niv
ers
ity
 L
ibr
ary
] a
t 0
4:3
2 2
5 O
cto
be
r 2
01
7 
progression of CF lung disease. J Cyst Fibros. [Internet].
2009;8 Suppl 1:S15–S19. Available from: http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=19460682
13. Robinson TE, Leung AN, Chen X, et al. Cystic fibrosis
HRCT scores correlate strongly with Pseudomonas
infection. Pediatr Pulmonol. [Internet]. 2009;44:1107–
1117. Available from: http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=
Citation&list_uids=19824046
14. Li Z, Sanders DB, Rock MJ, et al. Regional differences in
the evolution of lung disease in children with cystic
fibrosis. Pediatr Pulmonol. [Internet]. 2012;47:635–640.
Available from: http://www.ncbi.nlm.nih.gov/entrez/
query . fcgi?cmd=Retr ieve&db=PubMed&dopt=
Citation&list_uids=22162514.
15. Stick SM, Brennan S, Murray C, et al. Bronchiectasis in
infants and preschool children diagnosed with cystic
fibrosis after newborn screening. J Pediatr. [Internet].
2009;155:623–628.e1. Available from: http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=19616787.
16. Moss RB. Allergic bronchopulmonary aspergillosis and
Aspergillus infection in cystic fibrosis. Curr Opin Pulm
Med. [Internet]. 2010;16:598–603. Available from:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=
Retrieve&db=PubMed&dopt=Citation&list_uids=
20720494
17. Noni M, Katelari A, Dimopoulos G, et al. Aspergillus
fumigatus chronic colonization and lung function
decline in cystic fibrosis may have a two-way relation-
ship. Eur J Clin Microbiol Infect Dis. [Internet].
2015;34:2235–2241. Available from: http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=26319147
18. Speirs JJ, Van der Ent CK, Beekman JM. Effects of
Aspergillus fumigatus colonization on lung function in
cystic fibrosis. Curr Opin Pulm Med. [Internet].
2012;18:632–638. Available from: http://www.ncbi.nlm.
nih .gov/entrez/query . fcg i?cmd=Retr ieve&db=
PubMed&dopt=Citation&list_uids=22965276
19. Shoseyov D, Brownlee KG, Conway SP, et al.
Aspergillus bronchitis in cystic fibrosis. Chest.
[Internet]. 2006;130:222–226. Available from: http://
www.ncbi .nlm.nih.gov/entrez/query.fcgi?cmd=
Retrieve&db=PubMed&dopt=Citation&list_uids=
16840406
20. Gustafsson PM, De Jong PA, Tiddens HA, et al. Multiple-
breath inert gas washout and spirometry versus struc-
tural lung disease in cystic fibrosis. Thorax. [Internet].
2008;63:129–134. Available from: http://www.ncbi.nlm.
nih .gov/entrez/query . fcg i?cmd=Retr ieve&db=
PubMed&dopt=Citation&list_uids=17675316
21. Sanders DB, Li Z, Rock MJ, et al. The sensitivity of lung
disease surrogates in detecting chest CT abnormalities in
children with cystic fibrosis. Pediatr Pulmonol. [Internet].
2012;47:567–573. Available from: http://www.ncbi.nlm.
nih .gov/entrez/query . fcg i?cmd=Retr ieve&db=
PubMed&dopt=Citation&list_uids=22170734
22. Ellemunter H, Fuchs SI, Unsinn KM, et al. Sensitivity of
Lung Clearance Index and chest computed tomography
in early CF lung disease. Respir Med. [Internet].
2010;104:1834–1842. Available from: http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=20637585.
23. Owens CM, Aurora P, Stanojevic S, et al. Lung Clearance
Index and HRCT are complementary markers of lung
abnormalities in young children with CF. Thorax.
[Internet]. 2011;66:481–488. Available from: http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=21422040.
24. Rosenstein BJ, Cutting GR. The diagnosis of cystic
fibrosis: a consensus statement. Cystic Fibrosis
Foundation Consensus Panel. J Pediatr. [Internet].
1998;132:589–595. Available from: http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=9580754
25. Bilton D, Canny G, Conway S, et al. Pulmonary exacerba-
tion: towards a definition for use in clinical trials. Report
from the EuroCareCF Working Group on outcome para-
meters in clinical trials. J Cyst Fibros. [Internet]. 2011;10
Suppl 2:S79–S81. Available from: http://www.ncbi.nlm.
nih .gov/entrez/query . fcg i?cmd=Retr ieve&db=
PubMed&dopt=Citation&list_uids=21658647.
26. Pressler T, Frederiksen B, Skov M, et al. Early rise of anti-
pseudomonas antibodies and a mucoid phenotype of pseu-
domonas aeruginosa are risk factors for development of
chronic lung infection–a case control study. J Cyst Fibros.
[Internet]. 2006;5:9–15. Available from: http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=16412706
27. Armstead J,Morris J, DenningDW.Multi-country estimate
of different manifestations of aspergillosis in cystic fibrosis.
Plos One. [Internet]. 2014;9:e98502. Available from: http://
www.ncbi .nlm.nih.gov/entrez/query.fcgi?cmd=
Retrieve&db=PubMed&dopt=Citation&list_uids=
24914809
28. Wainwright CE, Vidmar S, Armstrong DS, et al. Effect of
bronchoalveolar lavage-directed therapy on Pseudomonas
aeruginosa infection and structural lung injury in children
with cystic fibrosis: a randomized trial. JAMA. [Internet].
2011;306:163–171. Available from: http://www.ncbi.nlm.
nih .gov/entrez/query . fcg i?cmd=Retr ieve&db=
PubMed&dopt=Citation&list_uids=21750293.
29. Loeve M, Gerbrands K, Hop WC, et al. Bronchiectasis
and pulmonary exacerbations in children and young
adults with cystic fibrosis. Chest. [Internet].
2011;140:178–185. Available from: http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=21148242
30. Proesmans M, Balinska-Miskiewicz W, Dupont L, et al.
Evaluating the “Leeds criteria” for Pseudomonas aeruginosa
infection in a cystic fibrosis centre. Eur Respir J. [Internet].
2006;27:937–943. Available from: http://www.ncbi.nlm.nih.
gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=
Citation&list_uids=16707392.
31. Lee TW, Brownlee KG, Conway SP, et al. Evaluation of
a new definition for chronic Pseudomonas aeruginosa
infection in cystic fibrosis patients. J Cyst Fibros.
[Internet]. 2003;2:29–34. Available from: http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=15463843
32. Pressler T, Bohmova C, Conway S, et al. Chronic
Pseudomonas aeruginosa infection definition: euroCareCF
8 T. KONGSTAD ET AL.
D
ow
nl
oa
de
d 
by
 [C
op
en
ha
ge
n U
niv
ers
ity
 L
ibr
ary
] a
t 0
4:3
2 2
5 O
cto
be
r 2
01
7 
Working Group report. J Cyst Fibros. [Internet]. 2011;10
Suppl 2:S75–S78. Available from: http://www.ncbi.nlm.nih.
gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=
Citation&list_uids=21658646.
33. Stevens DA, Moss RB, Kurup VP, et al. Allergic broncho-
pulmonary aspergillosis in cystic fibrosis–state of the art:
Cystic Fibrosis Foundation Consensus Conference. Clin
Infect Dis. [Internet]. 2003;37 Suppl 3:S225–S264.
Available from: http://www.ncbi.nlm.nih.gov/entrez/
query . fcgi?cmd=Retr ieve&db=PubMed&dopt=
Citation&list_uids=12975753.
34. Miller MR, Hankinson J, Brusasco V, et al.
Standardisation of spirometry. Eur Respir J. [Internet].
2005;26:319–338. Available from: http://www.ncbi.nlm.
nih .gov/entrez/query . fcg i?cmd=Retr ieve&db=
PubMed&dopt=Citation&list_uids=16055882.
35. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic refer-
ence values for spirometry for the 3-95-yr age range: the
global lung function 2012 equations. EurRespir J. [Internet].
2012;40:1324–1343. Available from: http://www.ncbi.nlm.
nih .gov/entrez/query . fcg i?cmd=Retr ieve&db=
PubMed&dopt=Citation&list_uids=22743675.
36. Koopman M, Zanen P, Kruitwagen CL, et al. Reference
values for paediatric pulmonary function testing: the
Utrecht dataset. Respir Med. [Internet]. 2011;105:15–
23. Available from: http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=
Citation&list_uids=20889322
37. Robinson PD, Latzin P, Verbanck S, et al. Consensus
statement for inert gas washout measurement using
multiple- and single- breath tests. Eur Respir J.
[Internet]. 2013;41:507–522. Available from: http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=23397305.
38. Mott LS, Park J, Gangell CL, et al. Distribution of early
structural lung changes due to cystic fibrosis detected
with chest computed tomography. J Pediatr. [Internet].
2013;163:243–248.e1–e3. Available from: http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=23357185.
39. Long FR, Williams RS, Adler BH, et al. Comparison of
quiet breathing and controlled ventilation in the high-
resolution CT assessment of airway disease in infants
with cystic fibrosis. Pediatr Radiol. [Internet].
2005;35:1075–1080. Available from: http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list_uids=16041581
40. Calder AD, Bush A, Brody AS, et al. Scoring of chest CT
in children with cystic fibrosis: state of the art. Pediatr
Radiol. [Internet]. 2014;44:1496–1506. Available from:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=
Retrieve&db=PubMed&dopt=Citation&list_uids=
25164326
41. Rosenow T, OudraadMC,Murray CP, et al. PRAGMA-CF.
A quantitative structural lung disease computed tomogra-
phy outcome in young children with cystic fibrosis. Am J
Respir Crit Care Med. [Internet]. 2015;191:1158–1165.
Available from: http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_
uids=25756857
Appendix
Computed tomography
All scans were performed by volumetric spiral CT imaging
on a Toshiba Aquillion 64 CT scanner (Toshiba
Corporation, Tokyo, Japan; 100 kVp, mAs-modulation;
SD=19 in inspiratory and SD=27 in expiratory sequences,
rotation 0.4 s). The average effective dose for both inspira-
tory and expiratoryCTwas 1.56mSv (range 0.76–4.05) and
calculated using age-specific conversion factors (E1).
CF-CT scoring
Good inter-observer agreement with a reference obser-
ver was secured prior to scoring the study cohort, using
training CTs that were scored by an experienced refer-
ence scorer.
Inter-observer agreement on training CF-CT scores
was calculated using intra-class correlation coefficients
for calculated total and subdomain scores, supplemen-
ted by weighted kappa statistics on individual observa-
tions for subdomains (coefficients ≥ 0.8 indicate
excellent agreement, 0.6–0.8 good agreement, 0.4–0.6
moderate agreement, 0.2–0.4 fair agreement, and <0.2
poor agreement), and Bland–Altman plots to display
signs of systematic bias in subdomains.
Inter-observer agreement on training CT scoring
using intra-class correlation coefficients ranged from
good (AT and airway wall thickening: 0.77) to excellent
(CF-CT total score: 0.88).
The weighted kappa statistics on every individual
observation ranged from moderate (0.43 (AWT), 0.48
(parenchyma), 0.53 (AT)) to good (0.71 (BE), 0.61
(mucus plugging), 0.67 (all scores combined)). Bland–
Altman plots showed no sign of systematic bias in any
of the sub-scores (Fig. E1).
Results
The included cohort was compared to the non-included
subjects and exhibited no significant differences, though
no patients in the non-included group had ABPA or
chronic P. aeruginosa infection (Table E1).
Reference
1. E1. Deak PD, Smal Y, Kalender WA. Multisection CT
protocols: sex- and age-specific conversion factors used to
determine effective dose from dose-length product.
Radiology. 2010; 257:158-66. doi: 10.1148/radiol.10100047.
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Table A1. Comparison between study cohort and excluded subjects.
Study cohort n=64 Non-included n=14 Test
Subjects Numbers % Numbers % p
Males 34 53 7 50 0.2
Homozygote Δ508 33 52 8 57 0.2
Chronic P. aeruginosa 5 6 0 0 0.4
ABPA 7 13 0 0 0.2
FEV1<80% 13 20 3 21 0.3
FVC<80% 5 8 2 14 0.3
Other characteristics (means) Study cohort Non-included p
Age (years) 12.3 13.3 0.3
BMI-z scores -0.1 -0.5 0.1
P. aeruginosa IgG precipitins 2.0 3.0 0.5
A. fumigatus IgG (EU) 48.7 55.3 0.8
S. aureus %positive cultures/year 33.9 34.0 1.0
ABPA: allergic bronchopulmonary aspergillosis. BMI: body mass index. EU: Elisa units.
Mucus plugging score =0.61 Parenchymal change score
=0.48
Air trapping score =0.53
Total score =0.67 Bronchiectasis score =0.71 Airway wall score =0.43
Figure A1. Bland–Altman plots for total score and subdomains assessing systematic bias between scorers in the training CTs done
prior to scoring the study cohort.
Figure A2. CF-CT total scores and percentage of gas trapping grouped according to infection status. (a) CF-CT total score, (b) gas
trapping score. $Non-significant, *p<0.01, compared to the non-infected group (Mann–Whitney test). Data are presented as box and
whiskers plots representing the 25th and 75th centiles and the range, respectively.
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